Randomized phase II trial of daily administration versus alternate-day administration of S-1 in patients with advanced non-small cell lung cancer

0Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

Objective The standard regimen of S-1 monotherapy, comprising 4 weeks of administration followed by 2 weeks of rest, frequently causes gastrointestinal toxicity. Studies indicate that alternate-day administration of S-1 decreases gastrointestinal toxicity in advanced gastric cancer. We conducted a randomized phase II trial among patients with previously treated non-small cell lung cancer (NSCLC) to compare safety and efficacy between alternate-day administration and the standard regimen. Patients and methods Patients were randomly assigned to the standard regimen (S-arm): S-1, 80–120 mg/day according to body surface area (BSA) daily for 4 weeks, followed by 2 weeks rest, every 6 weeks until progressive disease (PD) or alternate-day administration (A-arm): S-1, 80–120 mg/day according to BSA on Mondays, Wednesdays, Fridays and Sundays every week until PD. The primary endpoint was safety. Secondary endpoints included objective response, progression-free survival, overall survival, and completion rate of the first treatment cycle. Results In total, 61 patients were recruited: 31 to the S-arm, and 30 to the A-arm. In safety analysis, grade 3 or 4 adverse reactions were observed for 10 (32.3%; 95%CI: 15.8–48.7%) and 3 (10.0%; 95%CI:0-20.7%) patients in the S-arms and A-arms, respectively. The main grade 3 or 4 toxicities were anorexia, 19.4%/0%, and diarrhea, 9.7%/0%, respectively. No treatment-related death was observed. The objective response rate was 3.2% and 0.0%; the disease control rate was 45.2% and 56.7%, and the median progression-free survival was 2.7 months and 2.1 months in the S-arm and A-arm, respectively. The completion rate of the first cycle was 77.4% and 80.0%, respectively. Conclusion Alternate-day administration of S-1 demonstrated less toxicity without attenuating therapeutic effectiveness among patients with NSCLC. These are promising data to proceed on to validation studies of alternate-day administration of S-1.

Cite

CITATION STYLE

APA

Suzuki, A., Maemondo, M., Sugawara, S., Nakagawa, T., Taima, K., Inoue, A., … Nukiwa, T. (2017). Randomized phase II trial of daily administration versus alternate-day administration of S-1 in patients with advanced non-small cell lung cancer. Cancer Treatment and Research Communications, 12, 56–61. https://doi.org/10.1016/j.ctarc.2017.05.004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free